Paula Bekinschtein, MCIM

Thank you Nick McNally, Liz Pusey and UKRD for the opportunity to reflect on what's changed, what hasn't and what still needs to happen following my Clinical Trials Review in May 2023. The good news is that we've turned the corner. MHRA performance is radically improved and commercial trial recruitment numbers are significantally higher. We've got the first clinical trial delivery accelerators off the ground, in dementia and cancer vaccines, and it feels like this is a policy area that the government - and any future government - is determined to improve. The biggest challenge is still at site level. It's far too costly, bureaucratic and time-consuming to set up trials in the NHS, especially in hospitals, and we're not making the most of primary care. Solving this requires many things, all set out in the Review, but a good starting point would be total transparency of performance and income data for clinical trials at all levels - hospital, trust, ICB, health board, region and nation. As the saying goes, you don't value what you don't count. Change also requires leadership. The NHS could be the world's leading platform for health R&D. We have the science, the universities, the data, the workforce, the research charities, world-renowned KOLs, you name it. Whoever is Secretary of State (or the CEO of the NHS) after the election, let's make sure this is top of their list.

128

This week Henry Gregg, A+LUK’s Director of External Affairs and the Chair of the Taskforce for Lung Health, spoke on BBC Morning Live about how too few patients with severe asthma can access biologics. Biologics can have a transformative impact on patients living with severe asthma and have been shown to reduce hospitalisations by 60%. Despite the effectiveness of biologics, only 16% of severe asthma patients who may be eligible can access these life-changing medicines. It is unacceptable that the majority of patients with severe asthma are not getting the treatments to which they are entitled to. The Taskforce is calling for the #NHS10YearPlan to set ambitious targets to increase access to biologics.

4

Government announces £100M public-private investment to set up 20 new clinical research hubs across the UK   Read more-  https://lnkd.in/gS_4wuru #clinicalresearch #UKlifesciences #VPAGInvestmentProgramme #innovativetreatments  

2

📢 Keynote Speaker Announcement – ‘Psoriasis Update: What you need to know’ Conference – 22nd June 2024 Dr. Satveer Mahil, Consultant Dermatologist and Senior Lecturer at King's College London, helped establish PsoProtect and PsoProtectMe to track Covid-19's impact on psoriasis patients. Following their success, Dr Mahil launched mySkin at our Conference in 2023. Now one year later, she’s back to update us on mySkin findings on psoriasis and overall health. Don't miss this insightful talk. Talk title: mySkin: 1 year on Book now: https://ow.ly/gk9x50RSSXT #MedicalResearch #PsoriasisUpdate #Dermatology

1

For #media #investors: Richard sat down with Proactive to provide some commentary on today’s results and the rationale behind its planned trial in mechanically ventilated patients. Watch the full interview here: https://lnkd.in/e_TteV4a

8

📢 Why public-private partnerships are crucial for UK clinical trials 📢 NWEH welcomes comments from the Minister for Science Lord Vallance speaking yesterday (7 November) at the Financial Times Global Pharma and Biotech Summit in London, stating that Labour seek closer ties with commercial clinical industry to ignite innovation. NWEH is a Manchester based pioneer in clinical trial technologies, using transformative solutions and expertise to streamline clinical trial management, for trials that are smarter, faster and truer-to-life. Our expertise and technology have been long recognised resulting in our recently announced pilot that will test a new model for safely and securely finding participants for clinical trials, using the Medicine and Healthcare product Regulatory Agency’s (MHRA) Clinical Practice Research Datalink (CPRD) data services. This initiative aims to improve the speed, scale, inclusivity and representativeness of participants found for novel clinical trials. If successful, the new model could result in enhanced innovation and efficiencies in medical research, improving public access to clinical trials to support the discovery and validation of advanced approaches to treatment and be expanded across the UK. Discover more about the NWEH pilot here https://lnkd.in/enxVevw9 #ClinicalTrials #Innovation #Healthcare #LifeSciences #MHRA #CPRD #ClinicalResearch #Pharma #Pharmaceutical #DiscoverMore #DeliverBetter https://lnkd.in/e9mEjM5y

25

Advanced therapy medicinal products Here’s a new briefing: https://lnkd.in/enS2s7W3 For anyone in biotech, medical regulation, medical marketing, pharmaceuticals, policy making and patient advocacy 'Regulating Advanced Therapy Medicinal Products' in the UK after Brexit is an introduction to ATMPs and their applications, explores the EU and UK regulatory and governance pathway outlines the key changes resulting from the UK’s departure from the EU. You can read the full briefing here https://lnkd.in/enS2s7W3

9

At #ASCO24, we are delighted to share the key findings from sunvozertinib’s global pivotal WU-KONG1B study that has met its primary endpoint in EGFR exon20ins NSCLC. https://lnkd.in/eYZiT7jf #exon20ins #nsclc #oncology

12

🌟 MediSieve Featured on Fireside with Founders and Leaders!🎙️ We’re excited to share that our founder and CEO, Dr George Frodsham, recently joined Rupert McSheehy (rmg digital) on his podcast, Fireside with Founders and Leaders, to discuss the future of #healthcare and our revolutionary Magnetic Blood Filtration technology. The episode covers: 🔬 The personal story and inspiration behind MediSieve. 🔗 How physics, engineering, and biology converge to power our innovation. 💼 Overcoming regulatory and funding challenges in a unique biotech space. 🌍 A bold vision for the future of personalised medicine. If you're curious about the future of healthcare, this episode is not to be missed! 🎧 Tune in now: 👉 Apple: https://lnkd.in/e-5wAThn 👉 Spotify: https://lnkd.in/eh7M_2nb #Podcast #Biotech #Technology #Innovation #PrecisionMedicine #Healthcare #Leadership

8

Morelife is hosting a #WebinarMarathon this Thursday which includes a discussion on all aspects of the well-known instrument of ''Healthy Weight'' measurement - BMI. Please leave any questions you have on BMI for our Q&A in the comments below or email us on [email protected]! Stay tuned for the link to the published webinar! #BMI #Morelife #HaveYourSay #WeightManagement

8

So, who exactly is Avacta, and why should you care? Well, #AVCT is a British biotech company that’s spearheading innovations in cancer treatment. They’ve got two main divisions: Therapeutics, where they’re developing next-generation cancer drugs, and Diagnostics, which helps healthcare professionals with advanced testing tools. But it’s really their Therapeutics Division that’s turning heads, especially with their novel cancer treatment approach, aiming to target tumours more precisely than ever before. https://lnkd.in/ecvZ-mwX

3

Join Matthew Hewitt's presentation, “Fast technology coupled with deliberate regulatory: How can the field adapt new guidance to meet therapeutic demand?” CAR-TCR Summit Series As the number of CGT market approvals accelerates, Matt will discuss challenges in manufacturing and address how working collaboratively with partners and regulators aids in tackling the pain points of therapeutic development and clinical trial design. Don't miss this insightful session on regulatory guidance. https://okt.to/KTZMwk #cartcr #cgtdevelopment #celltherapy

17

Private equity firm Kester Capital has acquired Hitchin, Hertfordshire-based EMAS PHARMA LIMITED, the clinical development division of Bionical Emas https://lnkd.in/eE7EEmhj

6

Another candidate success story We love hearing success stories like this one from the brilliant Ruth Ajayi, who is currently an Associate Board Member for the Professional Standards Authority, the Lay Chair, for the Advisory Appointment Committee at Barts Health NHS Trust and the Chair, for the Genomics Medicines Services People Forum for NHS England. “Dynamic Boards has been a great help in my transition into a Non-Executive Director (NED) career. The wealth of resources, especially the YouTube channel and blogs, provided valuable guidance when I felt overwhelmed by the information available online. These resources reassured me that I had the necessary skills and experience to apply for NED roles, and I greatly appreciate that they are offered free of charge. Through Dynamic Boards, I have applied for several roles and was able to secure my first NED position via their job board. I often signpost people to Dynamic Boards who are starting out on their journey to becoming a NED, as it is an excellent starting point. The NED Community has also been very helpful. The blogs guided me in drafting my first NED CV and cover letter, and the community itself offers support and insights from people with diverse experiences. The networking events are particularly useful for expanding connections across the country, which is helping me grow as a NED both personally and professionally.” There are lots of people out there, like Ruth, that would make great NEDs but are put off by the invite-only groups and job sites that charge candidates to view roles, which are traditionally associated with the Non-Executive community. At Dynamic Boards, we want to ensure that everyone with the right skills, experience and perspectives have an equal opportunity at accessing Non-Executive roles across the UK, regardless of their background or contacts. This is why all of our services for candidates are free. We want to inspire those who might previously had not considered NED work before and encourage those in existing Non-Exec roles to be more thoughtful and effective board members. Learn more about Dynamic Boards here: https://lnkd.in/ev_DMeEC #nonexecutivedirectors #neds #dynamicboards #ruthajayi #boardroles #boardrecruitment #nedcareer #candidatefeedback

19

1 Comment